CN113439846A - Nutrient composition formula and health food for people with high uric acid and gout - Google Patents
Nutrient composition formula and health food for people with high uric acid and gout Download PDFInfo
- Publication number
- CN113439846A CN113439846A CN202110580077.0A CN202110580077A CN113439846A CN 113439846 A CN113439846 A CN 113439846A CN 202110580077 A CN202110580077 A CN 202110580077A CN 113439846 A CN113439846 A CN 113439846A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- nutrient composition
- vitamin
- people
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 95
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 94
- 229940116269 uric acid Drugs 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 34
- 201000005569 Gout Diseases 0.000 title claims abstract description 30
- 235000013402 health food Nutrition 0.000 title claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 58
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 52
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 22
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940046009 vitamin E Drugs 0.000 claims abstract description 22
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 22
- 239000011709 vitamin E Substances 0.000 claims abstract description 22
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 17
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 17
- 239000011718 vitamin C Substances 0.000 claims abstract description 17
- 235000013305 food Nutrition 0.000 claims abstract description 14
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000011591 potassium Substances 0.000 claims abstract description 9
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 35
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 13
- 239000001508 potassium citrate Substances 0.000 claims description 12
- 229960002635 potassium citrate Drugs 0.000 claims description 12
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 12
- 235000011082 potassium citrates Nutrition 0.000 claims description 12
- 229960000984 tocofersolan Drugs 0.000 claims description 12
- 241000167854 Bourreria succulenta Species 0.000 claims description 11
- 235000005979 Citrus limon Nutrition 0.000 claims description 11
- 244000131522 Citrus pyriformis Species 0.000 claims description 11
- 235000019693 cherries Nutrition 0.000 claims description 11
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 239000002076 α-tocopherol Substances 0.000 claims description 9
- 235000004835 α-tocopherol Nutrition 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- 239000002211 L-ascorbic acid Substances 0.000 claims description 8
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 8
- 239000004376 Sucralose Substances 0.000 claims description 8
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 8
- 229960003975 potassium Drugs 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 235000019408 sucralose Nutrition 0.000 claims description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 235000010755 mineral Nutrition 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 229940042585 tocopherol acetate Drugs 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 4
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 4
- 235000013599 spices Nutrition 0.000 claims description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 3
- 240000007087 Apium graveolens Species 0.000 claims description 3
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 3
- 235000010591 Appio Nutrition 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 3
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 3
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 3
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 3
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001387 apium graveolens Substances 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 229940093956 potassium carbonate Drugs 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 229960002816 potassium chloride Drugs 0.000 claims description 3
- 239000004224 potassium gluconate Substances 0.000 claims description 3
- 229960003189 potassium gluconate Drugs 0.000 claims description 3
- 235000013926 potassium gluconate Nutrition 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229940085605 saccharin sodium Drugs 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 229940047036 calcium ascorbate Drugs 0.000 claims description 2
- 239000011692 calcium ascorbate Substances 0.000 claims description 2
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 2
- 229960005055 sodium ascorbate Drugs 0.000 claims description 2
- 240000008790 Musa x paradisiaca Species 0.000 claims 2
- 244000298479 Cichorium intybus Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract description 22
- 230000029142 excretion Effects 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 235000015872 dietary supplement Nutrition 0.000 abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 4
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 208000017169 kidney disease Diseases 0.000 abstract description 4
- 230000007310 pathophysiology Effects 0.000 abstract description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract description 3
- 208000006011 Stroke Diseases 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 241000234295 Musa Species 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 241000723343 Cichorium Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 239000002967 calcium-L-ascorbate Substances 0.000 description 1
- 235000005937 calcium-L-ascorbate Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000013173 literature analysis Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- -1 oxygen radicals Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a uric acid reducing nutrient composition formula and health-care food for people with high uric acid and gout, and belongs to the technical field of nutrient supplement. The uric acid reducing nutrient composition formula for the crowds with high uric acid and gout comprises the following components: 6-500 mg of vitamin C, 1.5-150 mg of vitamin E and 250-2400 mg of potassium. Aiming at the pathophysiology of hyperuricemia, the invention reduces the production of endogenous purine, inhibits the generation of uric acid, promotes the excretion of uric acid, is beneficial to reducing blood uric acid, and can prevent and assist in treating gout; in addition, the invention is a nutrient supplement, has high safety, and can prevent gout, diabetes, metabolic syndrome, hyperlipidemia, chronic nephropathy, cardiovascular diseases and cerebral apoplexy caused by high uric acid after long-term administration.
Description
Technical Field
The invention belongs to the technical field of nutrient supplement, and particularly relates to a uric acid reducing nutrient composition formula and health food for people with high uric acid and gout.
Background
Uric acid is a product of purine metabolism in humans. There are two human purine sources, endogenous is self-synthesis or nucleic acid degradation (about 600 mg/d), accounting for about 80% of total uric acid in vivo; exogenous was a purine diet (approximately 100 mg/d) which accounted for approximately 20% of the total uric acid content in the body. Under normal conditions, the uric acid pool in the body is 1200 mg, about 750 mg of uric acid is produced every day, 800-1000 mg of uric acid is discharged, 30% of uric acid is excreted from intestinal tracts and biliary tracts, and 70% of uric acid is excreted through kidneys. Normally, the production and excretion of uric acid in a human body are basically kept in dynamic balance every day, and all factors influencing the production and/or excretion of blood uric acid can cause the increase of the blood uric acid level. When the blood uric acid exceeds the saturation concentration, the urate crystals can be directly adhered and deposited on the joints, peripheral soft tissues, renal tubules, blood vessels and other parts to chemotact neutrophils and macrophages; after the interaction between cells and crystals, inflammatory factors, metalloprotease, hydrolase and the like are released, and acute and chronic injuries such as articular cartilage, bone, kidney, blood vessel intima and the like are caused.
Along with the continuous improvement of the living standard of people in China and the change of dietary structure, the prevalence rate of hyperuricemia is continuously improved, the fact that the high prevalence rate is not contended is already provided, the endocrine society of the Chinese medical society in the Chinese expert consensus on hyperuricemia and gout treatment clearly indicates that the hyperuricemia and the gout are dense and indistinguishable, and are independent risk factors of metabolic diseases [ diabetes, metabolic syndrome, hyperlipidemia and the like ], chronic nephropathy, cardiovascular diseases and cerebral apoplexy, the multiple system damage can be caused, and the early correct treatment is favorable for reducing related complications or concomitant diseases.
Today's recommendations for both gout prevention and uric acid reduction suggest only a reduced purine-containing diet, which reduces the purine source by only 20%, but more importantly, reduces endogenous purine production and uric acid excretion.
At present, uric acid lowering treatment mainly comprises chemical drugs, including uric acid production inhibiting drugs (such as allopurinol and febuxostat) and uric acid excretion promoting drugs (such as benzbromarone and probenecid) with good curative effect, but the side effects of allergy, gastrointestinal reaction, liver and kidney function damage, bone marrow inhibition and the like caused by the drugs cannot be ignored. In the aspect of traditional Chinese medicine, the traditional Chinese medicine for reducing uric acid at present is mainly used for conditioning liver, spleen and stomach, kidney, bladder and other viscera, and medicines with sweet and warm properties, mild tonification, diuresis and dampness removal or medicines with bitter and cold properties, heat clearing and diuresis promoting are widely used, while the Chinese patent medicine indications on the market are basically directed at joint swelling and pain caused by gout, and literature analysis shows that most of researches on the traditional Chinese medicine for reducing uric acid are based on animal experiments or in vitro experiments, and the traditional Chinese medicine for treating hyperuricemia is lack of effective medicines.
The vitamins and minerals are available raw materials of health-care food, are safe and free of toxic and side effects, and can be taken for a long time, however, no mineral preparation or vitamin preparation and other similar products suitable for people with high uric acid and gout exist in the market at present, and the nutrient composition which is free of toxic and side effects and can be taken for a long time and is beneficial to reducing blood uric acid is developed and is not slow enough for reducing huge social loss caused by high uric acid, solving the trouble of patients and improving the life quality of the patients.
Disclosure of Invention
The purpose of the invention is as follows: provides a uric acid reducing nutrient composition formula and health food for people with high uric acid and gout, and aims to solve the problems in the prior art.
The technical scheme is as follows: the uric acid reducing nutrient composition formula for the crowds with high uric acid and gout comprises the following components in percentage by daily nutrient weight: 6-500 mg of vitamin C, 1.5-150 mg of vitamin E, 250-2400 mg of potassium, a proper amount of fruit and vegetable powder and a proper amount of flavoring agent.
In a further embodiment, the vitamin C is one or more of L-ascorbic acid, sodium L-ascorbate, calcium L-ascorbate and ascorbyl palmitate.
In a further embodiment, the vitamin E is one or more of D-alpha-tocopherol, D-alpha-tocopherol acetate, D-alpha-tocopherol succinate, dl-alpha-tocopherol acetate, dl-alpha-tocopherol and calcium vitamin E succinate, and the vitamin E is vitamin E embedded powder.
In further embodiments, the potassium is one or more of dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, potassium citrate, potassium carbonate, and potassium gluconate.
In a further embodiment, the fruit and vegetable powder is one or more of cherry powder, lemon powder, banana powder, celery or celery seed powder and chicory powder.
In a further embodiment, the flavoring agent is one or more of essence, spice, aspartame, sucralose, stevioside, saccharin sodium, sorbitol and xylitol; the essence is one or more of cherry essence, lemon essence and banana essence.
In further embodiments, the nutrient composition can be made into various forms including buccal tablets, chewable tablets, granules, hard capsules, powders, oral liquids, syrups.
In a further embodiment, the nutrient composition contains fat soluble vitamins, including vitamin E; contains water-soluble vitamins including vitamin C; contains minerals including potassium.
In a further embodiment, the nutrient composition is applied to preparing health-care food and food for people with high uric acid.
A health food for people with high uric acid and gout comprises the nutrient composition and food acceptable auxiliary materials, wherein the food comprises health food and common food.
Has the advantages that: a uric acid reducing nutrient composition formula and health food for people with high uric acid and gout are provided, aiming at the pathophysiology of hyperuricemia, the uric acid reducing nutrient composition formula and the health food can reduce the endogenous purine production, inhibit the uric acid production, promote the uric acid excretion and contribute to reducing the blood uric acid; wherein vitamin C, also called ascorbic acid, is a natural antioxidant in human body and is also a trace element necessary for human body; vitamin E refers to a class of substances with alpha-tocopherol activity, which is scavenger of oxygen radicals; the vitamin C and the vitamin E have synergistic effect, remove free radical ROS, reduce DNA damage and cell death, reduce the generation of endogenous purine and reduce uric acid generated by oxidative stress; both vitamin C and vitamin E can inhibit the production of xanthine oxidase (key enzyme for uric acid metabolism) and reduce the production of uric acid; in addition, vitamin C competitively inhibits the rate of reabsorption of uric acid by renal proximal tubules, accelerating excretion of uric acid; the potassium citrate is a nutritional supplement which is approved by WTO and FDA and has the function of alkalifying body fluid, and can increase the pH value of urine, increase the solubility of uric acid and promote the discharge of uric acid by alkalifying the urine.
The advantages of the nutrient composition of the invention are as follows:
(1) aiming at the pathophysiology formula of hyperuricemia, wherein the vitamin C and the vitamin E have synergistic effect, so that the endogenous purine production can be reduced, the uric acid production can be inhibited, and the uric acid excretion can be promoted;
(2) the potassium citrate alkalifies urine, promotes uric acid discharge, is beneficial to reducing blood uric acid, and can prevent and assist in treating gout;
(3) the invention is a nutrient supplement, each raw material is from the available raw materials of health food, the invention is safe and has no toxic or side effect, the components in the formula all accord with the corresponding national standard, and the nutrient supplement can prevent gout, diabetes, metabolic syndrome, hyperlipidemia, chronic nephropathy, cardiovascular diseases and cerebral apoplexy caused by high uric acid after long-term administration.
Drawings
Figure 1 is a table of the nutrient composition formulations of the present invention.
Detailed Description
In the following description, numerous specific details are set forth in order to provide a more thorough understanding of the present invention. It will be apparent, however, to one skilled in the art, that the present invention may be practiced without one or more of these specific details. In other instances, well-known features have not been described in order to avoid obscuring the invention.
The invention provides a uric acid reducing nutrient composition formula for people with high uric acid and gout, which comprises 6-500 mg of vitamin C, 1.5-150 mg of vitamin E, 250-2400 mg of potassium, a proper amount of fruit and vegetable powder, a proper amount of flavoring agent, health-care food and food acceptable auxiliary materials, wherein the components are uniformly mixed and prepared into different dosage forms with different specifications by a granulation process or not, and the fruit and vegetable powder and the flavoring agent are only used for regulating the taste of customers.
The vitamin C is one or more of L-ascorbic acid, L-sodium ascorbate, L-calcium ascorbate and ascorbyl palmitate; the vitamin E is one or more of D-alpha-tocopherol, D-alpha-tocopherol acetate, D-alpha-tocopherol succinate, dl-alpha-tocopherol acetate, dl-alpha-tocopherol and vitamin E calcium succinate, and the vitamin E is embedding powder; the potassium is one or more of dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, potassium citrate, potassium carbonate and potassium gluconate, and the potassium citrate is preferably selected; the fruit and vegetable powder is one or more of cherry powder, lemon powder, banana powder, celery or celery seed powder and chicory powder; the correctant is one or more of essence, spice, aspartame, sucralose, stevioside, saccharin sodium, sorbitol, and xylitol; the essence and the spice are one or more of cherry essence, lemon essence and banana essence; the nutrient composition can be made into various forms, including buccal tablet, chewable tablet, granule, hard capsule, powder, oral liquid, and syrup.
The nutrient composition mainly aims at the pathophysiology of hyperuricemia generation, and can reduce the generation of endogenous purine, inhibit the generation of uric acid, promote the excretion of uric acid and help to reduce blood uric acid, wherein the strong antioxidation of vitamin C and vitamin E can reduce the damage of DNA and cell death, thereby reducing the generation of endogenous purine, and the vitamin C and the vitamin E can also inhibit the generation of xanthine oxidase (key enzyme for uric acid metabolism) and reduce the generation of uric acid; in addition, vitamin C competitively inhibits the reabsorption rate of the renal proximal tubule on uric acid, and accelerates the excretion of uric acid; meanwhile, potassium citrate alkalifies urine, increases the pH value of the urine, increases the solubility of uric acid and promotes the discharge of uric acid.
The nutrient composition of the invention has the advantages that: (1) the formula is scientific and reasonable, the problem of hyperuricemia is solved in a targeted manner, specific vitamins and mineral substances with auxiliary treatment effects are supplemented, the generation of uric acid is inhibited, the excretion of uric acid is promoted, and the effect of reducing uric acid can be enhanced by adding fruit and vegetable powder rich in organic acid and fibers; (2) the problem of hypokalemia caused by self diet of hyperuricemia people or caused by taking febuxostat and other medicines is solved; (3) the raw materials are vitamins and minerals, so the health food is safe and has no toxic or side effect, is more suitable for the long-term taking requirement of people with high uric acid, and can prevent gout, diabetes, metabolic syndrome, hyperlipidemia, chronic nephropathy, cardiovascular and cerebrovascular diseases and other concomitant diseases caused by high uric acid.
Example 1
The daily dose is 4 tablets, each tablet is prepared from 125mg of L-ascorbic acid, 37.5mg of d-alpha-tocopherol (mass fraction is 50%), 415mg of potassium citrate, 376.7mg of sorbitol, 0.8mg of sucralose, 10mg of magnesium stearate, 30mg of cherry powder and 5mg of lemon essence by granulation and tabletting processes, and the weight of each tablet is 1.0 g.
Example 2
The daily dose is 1 bag, and the formula of each bag is that L-ascorbic acid 500mg, d-alpha-tocopherol (mass fraction is 50%) 150mg, potassium citrate 1660mg, sorbitol 552.6mg, sucralose 2.4mg, magnesium stearate 30mg, cherry powder 90mg and lemon essence 15mg, and the powder with the weight of 3.0g per bag is prepared by mixing and subpackaging processes.
Example 3
The daily dose is 1 bag, each bag has the following formula of 500mg of L-ascorbic acid, 150mg of d-alpha-tocopherol (mass fraction is 50%), 1660mg of potassium citrate, 552.6mg of sorbitol, 2.4mg of sucralose, 30mg of magnesium stearate, 90mg of cherry powder and 15mg of lemon essence, and granules with the weight of 3.0g per bag are prepared by granulation and split charging processes.
Example 4
The daily dose is 1 bag, each bag has the following formula of 500mg of L-ascorbic acid, 150mg of d-alpha-tocopherol (mass fraction is 50%), 1660mg of potassium citrate, 1506.8mg of sorbitol, 3.2mg of sucralose, 40mg of magnesium stearate, 120mg of cherry powder and 20mg of lemon essence, and granules with the weight of 4.0g per bag are prepared by granulation and split charging processes.
Example 5
The daily dose is 1 bag, each bag has the following formula of 500mg of L-ascorbic acid, 150mg of d-alpha-tocopherol (mass fraction is 50%), 1660mg of potassium citrate, 2461mg of sorbitol, 4mg of sucralose, 50mg of magnesium stearate, 150mg of cherry powder and 25mg of lemon essence, and granules with the weight of 5.0g in each bag are prepared by granulation and split charging processes.
The above is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and those skilled in the art can make various equivalent changes to the technical solution of the present invention within the technical idea of the present invention, and these equivalent changes are all within the protection scope of the present invention.
Claims (10)
1. The uric acid reducing nutrient composition formula for the crowds with high uric acid and gout is characterized by comprising the following components in parts by weight per day: 6-500 mg of vitamin C, 1.5-150 mg of vitamin E, 250-2400 mg of potassium, a proper amount of fruit and vegetable powder and a proper amount of flavoring agent.
2. The uric acid lowering nutrient composition formula for people with high uric acid and gout according to claim 1, characterized in that: the vitamin C is one or more of L-ascorbic acid, L-sodium ascorbate, L-calcium ascorbate and ascorbyl palmitate.
3. The uric acid lowering nutrient composition formula for people with high uric acid and gout according to claim 1, characterized in that: the vitamin E is one or more of D-alpha-tocopherol, D-alpha-tocopherol acetate, D-alpha-tocopherol succinate, dl-alpha-tocopherol acetate, dl-alpha-tocopherol and vitamin E calcium succinate, and the vitamin E is vitamin E embedding powder.
4. The uric acid lowering nutrient composition formula for people with high uric acid and gout according to claim 1, characterized in that: the potassium is one or more of dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, potassium citrate, potassium carbonate and potassium gluconate.
5. The uric acid lowering nutrient composition formula for people with high uric acid and gout according to claim 1, characterized in that: the fruit and vegetable powder is one or more of cherry powder, lemon powder, banana powder, celery or celery seed powder and chicory powder.
6. The uric acid lowering nutrient composition formula for people with high uric acid and gout according to claim 1, characterized in that: the correctant is one or more of essence, spice, aspartame, sucralose, stevioside, saccharin sodium, sorbitol, and xylitol; the essence is one or more of cherry essence, lemon essence and banana essence.
7. The uric acid lowering nutrient composition formula for people with high uric acid and gout according to claim 1, characterized in that: the nutrient composition can be made into various forms, including buccal tablet, chewable tablet, granule, hard capsule, powder, oral liquid, and syrup.
8. The uric acid lowering nutrient composition formula for people with high uric acid and gout according to claim 1, characterized in that: the nutrient composition contains fat-soluble vitamins, including vitamin E; contains water-soluble vitamins including vitamin C; contains minerals including potassium.
9. The uric acid lowering nutrient composition formula for people with high uric acid and gout according to claims 1-8, characterized in that: the nutrient composition is applied to the preparation of health-care food and food for people with high uric acid.
10. A health food for people with high uric acid and gout is characterized in that: comprising the nutrient composition of claim 1 and a food acceptable excipient, wherein the food comprises health food and general food.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110580077.0A CN113439846A (en) | 2021-05-26 | 2021-05-26 | Nutrient composition formula and health food for people with high uric acid and gout |
| CN202111662050.2A CN114128894A (en) | 2021-05-26 | 2021-12-31 | Uric acid reducing nutrient composition for people with high uric acid and gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110580077.0A CN113439846A (en) | 2021-05-26 | 2021-05-26 | Nutrient composition formula and health food for people with high uric acid and gout |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113439846A true CN113439846A (en) | 2021-09-28 |
Family
ID=77810291
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110580077.0A Withdrawn CN113439846A (en) | 2021-05-26 | 2021-05-26 | Nutrient composition formula and health food for people with high uric acid and gout |
| CN202111662050.2A Pending CN114128894A (en) | 2021-05-26 | 2021-12-31 | Uric acid reducing nutrient composition for people with high uric acid and gout and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111662050.2A Pending CN114128894A (en) | 2021-05-26 | 2021-12-31 | Uric acid reducing nutrient composition for people with high uric acid and gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN113439846A (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI23130A (en) * | 2009-09-24 | 2011-03-31 | Prof.dr. CENCIČ AVRELIJA | Composite dietetic milk draught and method for production of composite dietetic milk draught with reduced level of uric acid and purine compounds |
| CN110051002A (en) * | 2019-04-28 | 2019-07-26 | 杭州泽健医药科技有限公司 | A kind of pharmaceutical composition with anti-trioxypurine effect |
| CN111387483A (en) * | 2020-01-16 | 2020-07-10 | 山东特康药业有限公司 | Medical nutrition powder for patients with hyperuricemia and gout and preparation method thereof |
| CN112205555A (en) * | 2020-08-30 | 2021-01-12 | 私诺(北京)健康科技有限公司 | Solid beverage for promoting uric acid excretion in targeted mode |
| CN112690457A (en) * | 2020-12-24 | 2021-04-23 | 石药集团中诺药业（泰州）有限公司 | Nutrient composition formula for overweight and obese people |
| CN112806579A (en) * | 2021-01-18 | 2021-05-18 | 湖南慧泽生物医药科技有限公司 | Formula food for gout patients |
-
2021
- 2021-05-26 CN CN202110580077.0A patent/CN113439846A/en not_active Withdrawn
- 2021-12-31 CN CN202111662050.2A patent/CN114128894A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114128894A (en) | 2022-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2733455T3 (en) | Multivitamin and mineral nutritional supplements | |
| CN100361599C (en) | Antioxidative compositions | |
| EP1748705B1 (en) | Use of beta-cryptoxanthin | |
| KR101717893B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| CN108420854B (en) | Antifatigue composition for improving endurance performance | |
| US20070218126A1 (en) | Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis | |
| JP6228250B2 (en) | Polysaccharide digestion inhibitor | |
| WO2006067925A1 (en) | Hepatic function remedial agent | |
| CN114271490A (en) | Health formula containing SOD and ergothioneine and having anti-fatigue, antioxidant and anti-hangover effects | |
| Patel et al. | How much is too much? Exploring pseudohyperaldosteronism in glycyrrhizic acid toxicity from chronic licorice root consumption | |
| NO20001717L (en) | Serotonin-containing formulation for oral administration and use of the same | |
| TW201410238A (en) | COMPOSITION COMPRISING SESAMIN COMPOUND, gamma-ORIZANOL AND RICE GERM OIL | |
| CN113439846A (en) | Nutrient composition formula and health food for people with high uric acid and gout | |
| KR20210104952A (en) | Functional health food for defecaation inducement and diet | |
| CN101505748A (en) | Quercetin-containing compositions | |
| JP3433917B2 (en) | Nutritional composition for enhancing body protein accumulation efficiency | |
| JPH04501724A (en) | Treatment of osteoporosis | |
| Vinishdharma et al. | Vitamin C as a therapeutic healing agent. | |
| RU2670612C2 (en) | Composition for preventing or treating obesity containing a-lipoic acid and n-acetylcysteine as active ingredients | |
| JP2014218527A (en) | Anti-inflammatory agent for animals | |
| CN114680339A (en) | Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof | |
| WO2022013581A1 (en) | Nutritional supplement, suitable for oral administration, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity, for use in the maintenance of normal liver function | |
| KR102124880B1 (en) | Composition for preventing or treating peripheral neuropathy comprisiong decursin or derivates thereof | |
| CN108379455B (en) | Uric acid reducing composition | |
| KR20010046562A (en) | Composition for treatment of osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210928 |
|
| WW01 | Invention patent application withdrawn after publication |